Details for Patent: 7,572,834
✉ Email this page to a colleague
Which drugs does patent 7,572,834 protect, and when does it expire?
Patent 7,572,834 protects AZILECT and is included in one NDA.
Summary for Patent: 7,572,834
| Title: | Rasagiline formulations and processes for their preparation |
| Abstract: | The subject invention provides a pharmaceutical composition comprising N-propargyl-1(R)-aminoindan mesylate; a pharmaceutically acceptable carrier; and greater than 0.7 ppm but less than 30 ppm in total of a compound having the structure: ##STR00001## and any salts of the compound. |
| Inventor(s): | Sterling; Jeffrey (Jerusalem, IL), Lerner; David (Jerusalem, IL), Rosen; Harel (Ra'anana, IL), Bronov; Leonid (Netanya, IL), Medini-Green; Dalia (Pardes Hanna, IL), Iosefzon; Berta (Jerusalem, IL), Berger-Peskin; Tirtsah (Ra'anana, IL), Lidor-Hadas; Ramy (Kfar Saba, IL), Bahar; Eliezer (Tel Aviv, IL) |
| Assignee: | Teva Pharmaceutical Industries, Ltd. (Petach-Tikva, IL) |
| Application Number: | 11/634,916 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
More… ↓ |
Drugs Protected by US Patent 7,572,834
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva | AZILECT | rasagiline mesylate | TABLET;ORAL | 021641-001 | May 16, 2006 | AB | RX | Yes | No | 7,572,834 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Teva | AZILECT | rasagiline mesylate | TABLET;ORAL | 021641-002 | May 16, 2006 | AB | RX | Yes | Yes | 7,572,834 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
